Novel Agents in the
Treatment of Lung Cancer

New Approaches to First-Line Therapies

References

    1. 
  • Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
    • 2. 
  • Akerley WL, Langer CJ, Oh Y, et al. Acceptable safety of bevacizumab therapy in patients with brain metastases due to non-small cell lung cancer. J Clin Oncol 2008;26(Suppl):8043.
    • 3. 
  • Pirker R, Szczesna A von Pawel J, et al. FLEX: a randomized multicenter phase III study of cetuximab in combination with cislatin/vinorelbine versus cisplatin/vinorelbine alone in the first-line treatment of advanced non-small cell lung cancer. Lancet 2009;373:1525-31.
    • 4. 
  • Khambata-Ford S, Harbison C, Woytowitz D, et al. K-Ras mutation, EGFR-related, and exploratory markers as response predictors of cetuximab in first-line advanced NSCLC: retrospective analyses of the BMS099 trial. J Clin Oncol 2009 ;27(15S):8021.
    • 5. 
  • Belani C, Brodowicz T, Ciuleanu T, et al. Maintenance pemetrexed plus best supportive care versus placebo plus BSC: a randomized phase III study in advanced non-small cell lung cancer. J Clin Oncol 2009;27(18S):8000.
    • 6. 
  • Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51.
    • 7. 
  • Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97.
    • 8. 
  • Cappuzzo F, Ciuleanu T, Stelmakh L, et al on behalf of the SATURN investigators. SATURN: a double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J Clin Oncol 2009;27(18S):15s:8001.
    • 9. 
  • Miller VA, O'Connor P, Soh S, et al. for the ATLAS Investigators. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2009;27(18S):LBA8002.
    • 10. 
  • Mok T, Wu Y, Thongprasert S, Yang C, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Eng J Med 2009;361:947-57.
    • 11. 
  • Lin E, Li L, Guan G, et al. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res 2009;7:1466-76.
    • 12. 
  • Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005;65:671-80.
    • 13. 
  • Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004;165:35-52.
    • 14. 
  • Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-91.
    • 15. 
  • Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009;27:1227-34.
    • 16. 
  • Patel JD, Hensing TA, Rademaker A, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 2009;27:3284-9.
    • 17. 
  • Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
    • 18. 
  • Dahlberg SE. Clinical course of advanced non-small cell lung cancer (NSCLC) patients (pts) experiencing hypertension (HTN) during treatment (TX) with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P) on E4599. J Clin Oncol 2009;27(15S):8042.
    • 19. 
  • Dowlati A, Gray R, Johnson DH, et al. Prospective correlative assessment of biomarkers in E4599 randomized phase II/III trial of carboplatin and paclitaxel ± bevacizumab in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2006;24(18S):7027.
    • 20. 
  • Zhang W, Dahlberg SE, Yang D, et al. Genetic variants in angiogenesis pathway associated with clinical outcome in NSCLC patients (pts) treated with bevacizumab in combination with carboplatin and paclitaxel: subset pharmacogenetic analysis of ECOG 4599. J Clin Oncol 2009;27(15S):8032.
    • 21. 
  • Socinski MA, Langer CJ, Huang JE, et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 2009;27:5255-61.
    • 22. 
  • Thatcher N, Lynch TJ, Butts C, et al. Cetuximab plus platinum-based chemotherapy as 1st-line treatment in patients with non-small cell lung cancer (NSCLC): a meta-analysis of randomized phase II/III trials. Oral presentation (A3-7) at the 13th World Conference on Lung Cancer, San Francisco, July 31-August 4, 2009.
    • 23. 
  • Rosell R, Robinet G, Szczesna A, et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line treatment therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 2008;19:362-9.
    • 24. 
  • Butts CA, Bodkin D, Middleman EL, et al. Randomized phase II study of gemcitabine plus cisplatin or carboplatin, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non-small cell lung cancer. J Clin Oncol 2007;25:5777-84.
    • 25. 
  • Lynch TJ, Patel T, Dreisbach L, et al. A randomized multicenter phase III study of cetuximab (Erbutix) in combination with taxane/carboplatin versus taxane/carboplatin alone as first-line treatment for patients with advanced/metastatic non-small cell lung cancer (NSCLC). J Thor Oncol 2008;3(Suppl 4):S305.
    • 26. 
  • Pujol JL, Lynch T, Rosell R, et al. A meta-analysis of four randomized phase II/III trials adding cetuximab to platinum-based chemotherapy as 1st-line treatment in patients with non-small cell lung cancer (NSCLC). Eur J Cancer 2009;7(Suppl):S508;9009.
    • 27. 
  • Kim ES, Herbst RS, Moon J, et al. S0536: carboplatin, paclitaxel, cetuximab and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC), a SWOG phase II study. Poster presentation (PD 3.5.5) at the 13th World Conference on Lung Cancer, San Francisco, July 31-August 4, 2009.
    • 28. 
  • Mack PC, Holland WS, Redman M, et al. KRAS mutation analysis in cetuximab-treated advanced stage NSCLC: SWOG experience with S0342 and S0536. J Clin Oncol 2009:27(15S):8022.
    • 29. 
  • Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
    • 30. 
  • Thatcher N, Chang A, Parikh P, et al. Gefinitib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366:1527-37.
    • 31. 
  • Wacker B, Nagrani T, Weinberg J, et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007;13:3913-21.
    • 32. 
  • Moore MJ, Goldstein J, Hamm J, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the NCIC Clinical Trials Group. J Clin Oncol 2005;23(Suppl):1.
    • 33. 
  • Gatzemeier U, von Pawel J, Vynnychenko I, et al. FLEX: cetuximab in combination with platinum-based chemotherapy (CT) improves survival versus CT alone in the 1st-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2008;3(Suppl 4):S265:8.
    • 34. 
  • Neal JW, Woytowitz D, Patel T, et al. Skin rash as a surrogate marker of cetuximab efficacy in advanced NSCLC: a retrospective analysis of BMS099. Poster Presentation (PD 9.1.3) at the 13th World Conference on Lung Cancer, San Francisco, July 31-August 4, 2009.
    • 35. 
  • O'Byrne KJ, Bondarenko I, Barrios C, et al. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): data from the FLEX study. J Clin Oncol 2009;27(15S):8007.
    • 36. 
  • Hirsch FR, Herbst RS, Olsen C, et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 2008;26:3351-7.
    • 37. 
  • Paz-Ares L, Sanchez JM, Garcia-Velasco A, et al. Prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). J Clin Oncol 2006;24(18S):7020.
    • 38. 
  • Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003;21:2237-46.
    • 39. 
  • Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-58.
    • 40. 
  • Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non—small-cell lung cancer. J Clin Oncol 2004;22:3238-47.
    • 41. 
  • Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372:1809-18.
    • 42. 
  • Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
    • 43. 
  • Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
    • 44. 
  • Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-11.
    • 45. 
  • Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81.
    • 46. 
  • Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007;25:587-95.
    • 47. 
  • Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008;14:2895-9.
    • 48. 
  • Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26:2442-9.
    • 49. 
  • Inoue A, Suzuki T, Fukuhara T, et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006;24:3340-6.
    • 50. 
  • Asahina H, Yamazaki K, Kinoshita I, et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 2006;95:998-1004.
    • 51. 
  • Inoue A, Kobayashi K, Usui K, et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009;27:1394-400.
    • 52. 
  • Kobayashi K, Inoue A, Maemondo M, et al. First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations: a phase III study (002) by North East Japan Gefitinib Study Group. J Clin Oncol 2009;27(15S):8016.
    • 53. 
  • LeRoith D, Toberts CT. The insulinlike growth factor system and cancer. Cancer Lett 2003;195:12737.
    • 54. 
  • Yee D. Targeting insulin-like growth factor pathways. Br J Cancer 2006;94:465-8.
    • 55. 
  • Yuen JS, Macaulay VM. Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. Expert Opin Ther Targets 2008;12:589-603.
    • 56. 
  • Dziadziuszko R, Camidge DR, Hirsch FR. The insulin-like growth factor pathway in lung cancer. J Thorac Oncol 2008;3:815-8.
    • 57. 
  • Ryan PD, Goss PE. The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist 2008;13:16-24.
    • 58. 
  • Spitz MR, Barnett MJ, Goodman GE, et al. Serum Insulin like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-Carotene and Retinol Efficacy Trial Cohort. Cancer Epidemiol Biomarkers Prev 2002;11:1413-18.
    • 59. 
  • Han JY, Choi BG, Choi JY, Lee SY, Ju SY. The prognostic significance of pretreatment plasma levels of insulin-like growth factor (IGF)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small cell lung cancer. Lung Cancer 2006;54:227-34.
    • 60. 
  • Kato T, Hayama S, Yamabuki T, et al. Increased expression of insulin like growth factor-II messenger RNA binding protein 1 is associated with tumor progression in patients with lung cancer. Clin Cancer Res 2007;13:434-42.
    • 61. 
  • Kaiser U, Schardt C, Brandscheidt D, et al. Expression of insulinlike growth factor receptors I and II in normal human lung and in lung cancer. J Cancer Res Clin Oncol 1993;119:6658.
    • 62. 
  • Gualberto A, Melvin CL, Dean A, et al. Characterization of NSCLC patients responding to anti-IGF-IR therapy. J Clin Oncol 2008;26(Suppl):8000.
    • 63. 
  • Pollak M, Eisenberg P, Karp D, et al. Safety and tolerability of the anti-IGF-I receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in patients with advanced solid tumors. Amer Assoc Cancer Res Annual Meeting Proceedings 2007:LB-343.
    • 64. 
  • Attard G, Fong PC, Molife R, et al. Phase I trial involving the pharmacodynamic (PD) study of circulating tumour cells, of CP-751,871 (C), a monoclonal antibody against the insulin-like growth factor 1 receptor (IGF-1R), with docetaxel (D) in patients (p) with advanced cancer. J Clin Oncol 2006;24(18S):3023.
    • 65. 
  • Karp DD, Paz-Ares LG, Blakely LG, et al. Efficacy of the anti-insulin like growth factor I receptor (IGF-IR) antibody CP-751871 in combination with paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007;25(18S):7506.
    • 66. 
  • Karp DD, Paz-Ares LG, Novello S, et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 2009;27:2516-22.
    • 67. 
  • Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-53.
    • 68. 
  • Smith IE, O'Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001;19:1336-43.
    • 69. 
  • Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2002;20:1335-43.
    • 70. 
  • von Plessen C, Bergman B, Andresen O, et al. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer 2006;95:966-73.
    • 71. 
  • Belani CP, Barstis J, Perry MC, et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 2003;21:2933-9.
    • 72. 
  • Brodowicz T, Krzakowski M, Zwitter M, et al; Central European Cooperative Oncology Group CECOG. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006;52:155-63.
    • 73. 
  • Fidias P, Dakhil S, Lyss A, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small cell lung cancer. J Clin Oncol 2009;27:591-8.
    • 74. 
  • Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374: 1432-1440.
    • 75. 
  • Hopwood P, Stephens RJ. Symptoms at presentation for treatment in patients with lung cancer: implications for the evaluation of palliative treatment. The Medical Research Council (MRC) Lung Cancer Working Party. Br J Cancer 1995;71:633-6.
    • 76. 
  • Temel JS, Jackson VA, Billings JA, et al. Phase II study: integrated palliative care in newly diagnosed advanced non-small-cell lung cancer patients. J Clin Oncol 2007;25:2377-82.
    • 77. 
  • Vainio A. Prevalence of symptoms among patients with advanced cancer: an international collaborative study. Symptom Prevalence Group. J Pain Symptom Manage 1996;12:3-10.
    • 78. 
  • Tanaka K, Akechi T, Okuyama T, et al. Impact of dyspnea, pain, and fatigue on daily life activities in ambulatory patients with advanced lung cancer. Journal of Pain & Symptom Management 2002;23:417-23.
    • 79. 
  • Hudson PL, Aranda S, Kristjanson LJ. Meeting the supportive needs of family caregivers in palliative care: challenges for health professionals. J Palliat Med 2004;7:19-25.
    • 80. 
  • Temel JS, Greer JA, Admane S, et al. Illness understanding in patients with advanced lung cancer. J Clin Oncol 2009;27(15S):9515.
    • 81. 
  • Weeks JC, Cook EF, O'Day SJ, et al. Relationship between cancer patients' predictions of prognosis and their treatment preferences. JAMA 1998;279:1709-14.
    • 82. 
  • Wright AA, Zhang B, Ray A, et al. Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. JAMA 2008;300:1665-73.
    • 83. 
  • Lamont EB, Christakis NA. Prognostic disclosure to patients with cancer near the end of life. Ann Intern Med 2001;134:1096-105.
    • 84. 
  • Earle CC, Neville BA, Landrum MB, et al. Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol 2004;22:315-21.
    • 85. 
  • Zhang B, Wright AA, Huskamp HA, et al. Health care costs in the last week of life: associations with end-of-life conversations. Arch Intern Med 2009;169:480-8.
    • 86. 
  • Zimmermann C, Riechelmann R, Krzyzanowska M, et al. Effectiveness of specialized palliative care: a systematic review. JAMA 2008;299:1698-709.
    • 87. 
  • Follwell M, Burman D, Le LW, et al. Phase II study of an outpatient palliative care intervention in patients with metastatic cancer. J Clin Oncol 2009;27:206-13.
    • 88. 
  • Morita T, Akechi T, Ikenaga M, et al. Late referrals to specialized palliative care service in Japan. J Clin Oncol 2005;23:2637-44.
    • 89. 
  • Ferris FD, Bruera E, Cherny N, et al. Palliative cancer care a decade later: accomplishments, the need, next steps — from the American Society of Clinical Oncology. J Clin Oncol 2009;27:3052-8.
    • 90. 
  • Rabow MW, Dibble SL, Pantilat SZ, et al. The comprehensive care team: a controlled trial of outpatient palliative medicine consultation. Arch Intern Med 2004;164:83-91.
    • 91. 
  • Jordhoy MS, Fayers P, Loge JH, et al. Quality of life in palliative cancer care: results from a cluster randomized trial. J Clin Oncol 2001;19:3884-94.
    • 92. 
  • Bakitas M, Lyons KD, Hegel MT, et al. Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. JAMA 2009;302:741-9.
    • 93. 
  • Morrison RS, Penrod JD, Cassel JB, et al. Cost savings associated with US hospital palliative care consultation programs. Arch Intern Med 2008;168:1783-90.
    • 94. 
  • Gavrilovic IT, Posner JB. Brain metastases: epidemiology and pathophysiology. J Neurooncol 2005;75:5-14.
    • 95. 
  • Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004;22:2865-72.
    • 96. 
  • Schouten LJ, Rutten J, Huveneers HA, et al. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002;94:2698-705.
    • 97. 
  • Delattre JY, Krol G, Thaler HT, et al. Distribution of brain metastases. Arch Neurol 1988;45:741-4.
    • 98. 
  • Ewing J. Metastasis. In: Ewing J (ed). Neoplastic Diseases: A Treatise on Tumours. Philadelphia, Saunders, 1940, pp 62-74.
    • 99. 
  • Mehta MP, Rodrigus P, Terhaard CH, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 2003;21:2529-36.
    • 100. 
  • Meyers CA, Weitzner MA, Valentine AD, et al. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 1998;16:2522-7.
    • 101. 
  • Shaw EG, Rosdhal R, D'Agostino RB, Jr, et al. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol 2006;24:1415-20.
    • 102. 
  • Wen PY, Schiff D, Kesari S, et al. Medical management of patients with brain tumors. J Neurooncol 2006;80:313-32.
    • 103. 
  • Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2000;54:1886-93.
    • 104. 
  • Eichler AF, Loeffler JS. Multidisciplinary management of brain metastases. Oncologist 2007;12:884-98.
    • 105. 
  • Mintz AH, Kestle J, Rathbone MP, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 1996;78:1470-6.
    • 106. 
  • Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990;322:494-500.
    • 107. 
  • Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004;363:1665-72.
    • 108. 
  • Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006;295:2483-91.
    • 109. 
  • Patchell RA, Tibbs PA, Regine WF, et al. Post-operative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998;280:1485-9.
    • 110. 
  • Suh JH, Stea B, Nabid A, et al. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J Clin Oncol 2006;24:106-14.
    • 111. 
  • Lin NU, Paul D, Lossignol D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009;15:1452-9.